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1. Introduction 
1.1 Etiology 
Graves’ disease is an autoimmune syndrome where thyroid stimulating antibodies bind to 
and activate the thyrotropin receptor on thyroid cells resulting in hyperthyroidism 
(Weetman, 2000; Jonklaas, 2011). Specifically, the production of thyroid-stimulating 
immunoglobulin (TSI) and thyroid-stimulating hormone-binding inhibitory 
immunoglobulin (TBII) act on the thyroid stimulating hormone receptor to cause thyroid 
stimulation or thyroid inhibition, respectively.  
Graves’ disease is the most common cause of hyperthyroidism in the United States with an 
estimated prevalence of 3 per 1,000 (Jonklaas, 2011, Abalovich, 2007). The occurrence of 
Graves’ disease is similar in Caucasians and Asians, with a lower incidence in African 
Americans (Weetman, 2000; Jonklaas, 2011). Major risk factors for Graves’ disease include 
female gender and genetic predisposition. Graves’ disease is approximately eight times 
more common in women than men and often occurs in clusters in families (Weetman, 2000). 
An increased frequency of certain human leukocyte antigens (HLAs) has also been 
associated with Graves’ disease. In Caucasians, HLA-D3 is present in approximately 50 
percent of patients. The presence of both HLA-B8 and HLA-D3 indicates a fourfold increase 
in the risk of developing Graves’ disease (Jonklaas, 2011).  
1.2 Signs and symptoms 
Common symptoms of hyperthyroidism may present as irritability, hyperactivity, altered 
mood, insomnia, fatigue, heat intolerance, increased sweating, palpitations, dyspnea, 
pruritis, weight loss with increased appetite, thirst and polyuria, increased stool frequency, 
oligomenorrhea or amenorrhea, and loss of libido.  Hyperthyroidism signs may include fine 
tremor, hyperkinesis or hyperreflexia, warm, moist skin, palmar erythema, hair loss, muscle 
weakness and wasting, sinus hypertension, tachycardia, atrial fibrillation, and/or heart 
failure. When hyperthyroidism is left untreated, manifestations of Graves’ disease may 
appear such as diffuse goiter, ophthalmopathy, retrobulbar pressure or pain, scleral 
injection, eyelid lag or retraction, exophthalmos, localized dermopathy, lymphoid 
hyperplasia, or thyroid acropachy. Conditions associated with Graves’ disease may 
comprise of type 1 diabetes mellitus, Addison’s disease, pernicious anemia, alopecia areata, 
vitiligo, myasthenia gravis, or celiac disease (Weetman, 2000).  
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1.3 Diagnosis 
The American Association of Clinical Endocrinologists and the American Thyroid 
Association recommend reflect same (TSH) testing as an initial test for screening and 
evaluation of symptomatic disease (Bahn, 2011). Laboratory results in Graves’ disease show 
an overall increase in both free triiodothyronine (FT3) and free thyroxine (FT4) with a 
disproportionate increase in triiodothyronine (T3) to thyroxine (T4). Values for serum T3 and 
T4 are elevated due to the saturation of thyroid binding globulin. However, levels for FT3 
and FT4 are elevated to a greater extent than serum values. Reflect same (TSH) is suppressed 
to the undetectable range (Weetman, 2000; Jonklaas, 2011).  
1.4 Treatment 
Current treatments for Graves’ disease include radioactive iodine, surgery, and antithyroid 
drugs such as propylthiouracil (PTU), methimazole, and carbimazole (a precursor molecule 
to methimazole not available in the US). Selection of the treatment modality varies greatly 
by geographic location with radioactive iodine being the treatment of choice in the United 
States and antithyroid drugs in most other countries (Weetman, 2000; Cooper, 2005; 
Jonklaas, 2011). In addition to geographic location, other aspects influence the selection of 
the most appropriate treatment such as: time to initial improvement, planning pregnancy, 
pregnancy or breastfeeding, size of the goiter, age of patient, likelihood of side effects, 
concurrent severe ophthalmopathy, interference with daily activities, and the likelihood of 
recurrence after treatment (Weetman, 2000).  
1.4.1 Thioamides 
Antithyroid drugs, thioamides, decrease thyroid hormone synthesis by inhibiting thyroid 
peroxidase catalyzed iodination of thyroglobulin and by inhibiting iodotyrosine coupling. 
Therefore, these drugs do not cure Graves’ disease but only control hyperthyroidism. 
Propylthiouracil has an added mechanism of action by reducing the peripheral conversion 
of T4 to T3. The American Thyroid Association and the American Association of Clinical 
Endocrinologists recommend methimazole as the preferred antithyroid drug in any patient 
with Graves’ disease except during the first trimester of pregnancy (Bahn, 2011).  
The initial dosing of either thioamide is empirical. The American Thyroid Association 
recommends a starting dose of 10-40 mg of methimazole or 100-600 mg of PTU daily in 
nonpregnant women. The pharmacokinetics of the thiamides are distinct.  Methimazole’s 
onset of action is 12-18 hours with a duration of action of 36-72 hours. The peak plasma 
concentration of methimazole is reached within 1-2 hours of ingestion and the half-life is 4-6 
hours after oral administration and has an oral bioavailability of 93% (Clark, 2006). Dosing 
depends on the severity of hyperthyroidism, 15 mg/day for mild up to 60 mg/day for 
severe hyperthyroidism. Based on the pharmacokinetics, the daily dose is divided into three 
doses, given every 8 hours. Methimazole is metabolized in the gastrointestinal system and 
first pass through the liver.  
The peak plasma concentration of PTU is reached within 1-2 hours of ingestion and the 
elimination half-life is 1-2 hours. The oral bioavailability of PTU is 53-88% and the duration 
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of action is 12-24 hours. Again, dosing depends on the severity of hyperthyroidism but 
usually is 100-300 mg/day divided into 3 doses, every 8 hours.  
The pharmacokinetics of PTU and methimazole in pregnant women are similar to non-
pregnant women (Clark, 2006). However, the metabolism and excretion of these drugs are 
increased in pregnant women with hyperthyroidism, due to an increased metabolic state of 
pregnancy.  Therefore, during pregnancy women may require a higher daily dose of 
antithyroid drug, such as PTU 300-450 mg per day or methimazole 30-40 mg per day.  
Propylthiouracil is highly protein bound (80-85%) whereas, methimazole has neglible protein 
binding. It was thought PTU was less likely to cross the placenta compared to methimazole 
(Clark, 2006). To address the theory that PTU has less fetal transfer than methimazole, 
Mortimer et al. evaluated the maternal to fetal transfer in nine isolated human placental 
lobules perfused with low and high doses of PTU and methimazole (Mortimer, 1997).  
Placentas were collected from euthyroid women with no history of antithyroid drug ingestion. 
All placentas were delivered at term by cesarean. Both PTU and methimazole readily crossed 
the placenta achieving steady state concentrations in approximately two hours. Both drugs 
demonstrated similar transfer kinetics, were nonsaturable, and were unaffected by the 
addition of bovine albumin to the perfusate. The authors concluded that PTU and 
methimazole had similar placental transfer kinetics. Therefore the rationale that PTU has less 
fetal transfer than methimazole was not supported in this well established model of drug 
transfer across the human placenta (Mortimer, 1997). So although, methimazole has neglible 
protein binding, methimazole has similar placental transfer compared to PTU. 
Because propylthiouracil has a shorter half-life, higher protein binding, and less drug 
concentration in breast milk, some providers view PTU as a safer option in breastfeeding. 
However, the American Academy of Pediatricians considers both compatible with 
breastfeeding (AAP, 2001). Nonetheless, methimazole has been found sufficient amounts in 
breastfed infants to cause thyroid dysfunction. Low doses of methimazole (<20 mg/day) 
have not been shown to be a serious risk to nursing infants (Cooper, 2009; Marx, 2009). 
Doses of propylthiouracil of less than 300 mg a day is recommended (Marx, 2009; 
Abalovich, 2007). It is recommended to have the mother take the antithyroid drug after 
breastfeeding (Marx, 2009). Monitoring the infant’s thyroid function while the nursing 
mother is taking either antithyroid drug is advised.    
One of the serious, rare side effects of thioamides is agranulocytosis, presenting with a fever, 
sore throat and an absolute granulocyte count of less than 500 per cubic millimeter. 
Thioamide-induced agranulocytosis has an incidence of 0.1-0.4% among the thioamides, is 
not dose related, and usually occurs within the first 90 days of therapy. If suspected, a 
complete blood count should be drawn and the medication should be immediately 
discontinued. Unfortunately, there is a significant likelihood of cross reaction among the 
thioamides so switching to another thioamide should not be an option. Routine white blood 
count monitoring has not been helpful in prevention because the thioamide-induced 
agranulocytosis occurs rapidly. However, a baseline assessment of the patient’s white blood 
cell count is recommended prior to initiation of the thioamide.  
Other side effects include leucopenia, thrombocytopenia, hepatitis, and vasculitis. Vasculitis 
has been reported more often with PTU and results in glomerulonephritis and diffuse 
alveolar hemorrhage (Kang, 2006). Methimazole has been reported to have a 33% chance of 
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cross reaction to PTU-induced vasculitis. More common side effects for both methimazole 
and PTU include fever, rash, arthritis, nausea, anorexia, and loss of taste or smell. 
(Weetman, 2000; Garcia-Mayor, 2010) The incidence of thioamide side effects is similar 
among pregnant and non-pregnant women. Side effects to methimazole are dose-related; 
PTU is less dose-related (Garcia-Mayor, 2010). Cross reactivity to thioamide-induced 
adverse events between the two agents may be as high as 50% (Garcia-Mayor, 2010).  
2. Graves’ disease in pregnancy 
It is estimated that hyperthyroidism is present in approximately 0.1-0.2% of pregnancies 
(Miehle, 2003; Mestman, 2004; Galofre, 2009). Of those pregnancies, neonatal Graves’ disease 
occurs in 1-5% of those babies (Fitzpatrick, 2010; Marx, 2008). Hyperthyroidism is the 
second most common endocrine disorder that occurs during pregnancy, following only 
diabetes mellitus (Mestman, 1998). Graves’ disease is the most common cause of 
hyperthyroidism during pregnancy, accounting for 85-95% of the cases (Galofre, 2009; 
Ecker, 2000). Another cause of hyperthyroidism results from overstimulation of the thyroid 
gland via human chorionic gonadotropin (hCG). This syndrome, known as gestational 
transient thyrotoxicosis (GTT), occurs during the first half of gestation due to hyperemesis 
gravidarum and is less severe than hyperthyroidism due to Graves’ disease (Glinoer, 2003).  
2.1 Etiology 
Thyroid function changes during pregnancy due to the elevated hCG, an increase in estrogen 
that increases circulating thyroid binding globulin levels which is the major transport protein 
for thyroid hormone, and a decrease in iodide due to increased renal clearance and losses due 
to the fetus and placenta (Marx, 2009). Before 12 weeks gestation, significant fetal brain 
development occurs through maternal thyroid hormones. After 12 weeks gestation, the fetal 
thyroid gland concentrates iodine and synthesizes thyroid hormone and continues fetal brain 
development (Morreale, 2000; Inoue, 2009; Abalovich, 2007).  
2.2 Signs and symptoms 
Pregnancy complicated by Graves’ disease usually presents with symptoms appearing in the 
first trimester, improving in the second and third trimesters, and reappearing in the 
postpartum period (Mestman, 2004; Inoue, 2009). Significant fetal and maternal complications 
can occur if the condition is left untreated. Specifically, spontaneous abortion, preterm 
delivery, stillbirth, low birth weight, preeclampsia, heart failure, and thyroid storm are known 
complications (Mestman, 2004; Inoue, 2009; Marx, 2009). Low birth weight has been reported 
to occur nine times as often compared to pregnancies not complicated by hyperthyroidism 
(Millar, 1994). Neonatal hyperthyroidism, prematurity and intrauterine growth retardation 
may occur. A 5.6% incidence of fetal death or stillbirth and a 5% incidence of fetal and neonatal 
abnormalities have been reported (Hamburger, 1992). Unfortunately, fetal and neonatal risks 
associated with Graves’ disease may be related to either the disease or the treatment of the 
disease. Since Graves’ disease is mediated by antibodies that cross the placenta, the risk of 
immune-mediated hypothyroidism and hyperthyroidism may develop in the neonate (ACOG, 
2002; Inoue, 2009). Women with Graves’ disease have TSI and TBII that can stimulate or inhibit 
the fetal thyroid, causing fetal hyperthyroidism or hypothyroidism, respectively. There is no 
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clinical correlation between the levels of antibodies and disease severity (Rashid, 2007). 
Occasionally, the antibodies may change during pregnancy from stimulation to inhibition of 
the TSH receptor (Laurberg, 2009).  
2.3 Diagnosis 
The American Association of Clinical Endocrinologists and the American Thyroid 
Association recommends measuring TSH but also FT4 or free thyroxine index (FTI) in 
symptomatic pregnant women. The FT4 rises in the first trimester due to the high circulating 
levels of human chorionic gonadotropin. Rarely hyperthyroidism during pregnancy is due 
to an abnormally high level of FT3 instead of high FT4. The TSH receptor antibody tests, TSI 
and TBII, may be helpful since these antibodies have been associated with infants born with 
hypothyroidism. If a pregnant woman has a low TSH but a normal FT4, subclinical 
hyperthyroidism is diagnosed and requires no treatment since treatment in this group has 
not been shown to improve pregnancy outcomes (Abalovich, 2007). 
2.4 Treatment 
It has been shown that hyperthyroidism in a pregnant woman should be treated to lessen 
the fetal and neonatal risks. The highest complications were associated with the poorest 
control and the best control was associated with the least complications (Abalovich, 2007). 
Therefore, the goal of treatment is to achieve the high euthyroid or low hyperthyroid range 
(maternal FT4 at or slightly higher than the upper limit of the normal nonpregnant reference 
range) and maintain this range throughout pregnancy in order to improve pregnancy 
outcomes (Chan, 2007). To accomplish this, antithyroid drugs are the preferred treatment 
during all stages of pregnancy. Radioactive iodine is contraindicated during pregnancy; 
inappropriate radioiodine administration given after 10-12 weeks destroys the fetal thyroid 
and results in neonatal hypothyroidism and cretinism (Gorman, 1999; Abalovich, 2007). 
Surgery is reserved for patients who require large doses of antithyroid drugs, or those who 
demonstrate poor medication adherence and continue to remain hyperthyroid (Cooper, 
2005; Miehle &Paschke, 2003; Mestman, 2004; Mestman, 1998; Glinoer, 2003; Karabinas & 
Tolis, 1998; Masiukiewicz &Burrow, 1999; Atkins, Cohen & Phillips, 2000). If surgery is 
necessary, surgery is preferred during the second trimester to decrease the risk of 
spontaneous abortion (Galofre, 2009). 
2.4.1 Thioamides 
During pregnancy, women may require a higher daily dose of antithyroid drug. 
Propylthiouracil should be given 100-150 mg three times daily or methimazole 30-40 mg per 
day until the patient becomes euthyroid. Upon euthyroid, the dose may be reduced to the 
lowest amount to maintain the euthyroid state with serum T4 at the upper end of normal 
and continued throughout pregnancy and labor. Improvement in FT4 is usually seen in 4 
weeks; whereas improvement in TSH occurs in 6-8 weeks (Galorfre, 2009). It is important 
not to overtreat because it may result in maternal or fetal hypothyroidsm (Casey, 2006). 
Therefore, monitoring is crucial; TSH and FT4 every 2 weeks and then every 4-6 weeks when 
euthyroidism is achieved (Clark, 2006).    
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2.4.1.1 Teratogenicity 
Historically, PTU has been the drug of choice when treating Graves’ disease during pregnancy 
in the United States.  Throughout the rest of the world, methimazole and carbimazole, are 
widely used to treat hyperthyroidism in pregnant women (Mandel, 2001; Dwarakanath, 1999). 
Methimazole has been linked to at least 25 reported cases of aplasia cutis, as well as at least 22 
cases of esophageal or choanal atresia or a combination of both (Mestman, 2004; Mandel, 2001; 
Ferraris 2003; Hamburger, 1992; Van Dijke, 1987; Karlson, 2002; Seoud,2003; Kannan, 2008; 
Karg, 2004). Methimazole has been described as “methimazole embryopathy” in children 
exposed to methimazole during the first trimester of pregnancy, especially during the first 7 
gestational weeks (Karlsson, 2002; Clementi, 1999). The embryopathy includes congenital 
anomalies such as choanal or esophageal atresia or aplasia cutis and developmental delay, 
hearing loss, and dysmorphic facial features (Chan, 2007).  
An evaluation of 49,091 live births estimated the incidence of aplasia cutis in the general 
population to be 0.03% or 0.05% of congenital skin defects (Van Dijke, 1987).  DiGianantonio 
and colleagues prospectively compared 241 women exposed to methimazole during 
pregnancy to 1,089 pregnant controls. No increased incidence of spontaneous or induced 
abortions or major congenital anomalies was reported in the methimazole cohort 
(DiGianantonio, 2001). Although a possible association between methimazole exposure 
during pregnancy and fetal congenital defects may exist, it has not been proven and may be 
secondary to hyperthyroidism (Briggs, 2011).  
At least 7cases of congenital anomalies have been reported in newborns exposed to PTU. A 
causal relationship between PTU exposure and congenital anomalies has not been found 
(Briggs, 2011). The Israeli Teratology Information Service reported that the rate of major 
anomalies was comparable between PTU-exposed pregnancies and controls (Rosenfeld, 
2009). At least 47 reports have been published describing PTU-related hepatic impairment in 
adults and children, approximately 0.1-0.5% in adults (Cooper, 1999; Cooper, 2009; 
Kontoleon, 2002; Patil-Sisodia, 2010). However, only one case has been reported of neonatal 
hepatitis secondary to transplacental propylthiouracil (Hayashida, 1990). Therapy with PTU 
should be discontinued since 25% of affected patients may progress to fulminant, fatal 
hepatic failure (Kontoleon, 2002; Patil-Sisodia, 2010). The incidence of PTU hepatic failure 
does not correlate to PTU dosage or duration or patient age (Patil-Sisodia, 2010).  
The United States Food and Drug Administration classifies PTU and methimazole as Category 
D because of the potential for fetal hypothyroidism, rather than the potential teratogenicity. 
The American College of Obstetricians and Gynecologists (ACOG) recommends that either 
PTU or methimazole may be used to treat pregnant women with hyperthyroidism. 
The “block and replace” regimen that adds levothyroxine with an antithyroid drug is not 
recommended in pregnant women (Marx, 2009). It was originally thought that the placental 
transfer of levothyroxine would prevent fetal hypothyroidism. Levothyroxine and 
methimazole administered concomitantly to pregnant women with Graves’ disease has 
shown to reduce the incidence of postpartum hyperthyroidism (Hashizume, 1992). 
However, the necessary dose of the antithyroid drug is much higher when given with 
levothyroxine that fetal goiter and fetal hypothyroidism may still occur. Furthermore, the 
risk of fetal hypothyroidism is increased because the antithyroid medications but not 
levothyroxine cross the placenta (Rosenfeld, 2009).  
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2.4.1.2 Clinical trials 
Clinical studies support that fetal thyroid function outcomes are similar between the two 
drugs (Mortimer, 1997; Marchant, 1977; Momotani, 1997).  A retrospective chart review of 
135 patients with a history or diagnosis of hyperthyroidism at a high risk obstetrics clinic 
over a 16 year time period (1974 to 1990) compared the use of PTU and methimazole to treat 
hyperthyroidism during pregnancy (Wing, 1994). Of the 135 patients, 99 (73.3%) received 
PTU and 36 (26.7%) received methimazole.  Selection of the treatment agent was based 
solely on physician preference. Six of the patients received both PTU and methimazole and 
were therefore excluded from analysis. 
Diagnosis of hyperthyroidism was based on history, physical exam, thyroid-stimulating 
hormone, free thyroxine index, and free triiodothyronine index. The time required to 
normalize free FT4 levels and the incidence of congenital malformations or fetal 
hypothyroidism were evaluated. Maternal and fetal outcomes were obtained via 
retrospective chart review from clinic, labor, delivery, and postpartum records. Baseline 
characteristics for the two treatment groups were similar with respect to age, ethnicity, and 
parity.  
Maternal results showed that gestational age had no effect on the time to free FT4 
normalization. The median time to normalization was 7 weeks for the methimazole-treated 
group and 8 weeks for the PTU-treated group (p=0.34). The Cox proportional hazard 
compared the time of normalization between the two groups after adjusting for the initial 
measurements with no statistical difference between the PTU-treated group and the 
methimazole-treated group (p=0.52). Of the 135 pregnancies, four infants (3%) were born 
with congenital anomalies to mothers treated with either PTU or methimazole. Of these four 
infants, three (3%) of the fetal anomalies occurred in the 99 women who were treated with 
PTU and one (2.7%) occurred in the 36 women treated with methimazole. Fetal anomalies 
reported were ventricular septal defect, patent ductus arteriosus, and severe pulmonic 
stenosis in the infants of the PTU-treated mothers, and congenital inguinal hernia in the 
infant of the methimazole-treated mother. No cases of aplasia cutis were reported in either 
group. Congenital hypothyroidism occurred in one infant of a PTU-treated mother. The 
authors concluded that the incidence of congenital anomalies were consistent with the 
national average of 2% to 5% in the general population. The authors concluded that both 
PTU and methimazole were equally safe and effective in the treatment of hyperthyroidism 
during pregnancy (Wing, 1994). Potential limitations to the study were mostly due to the 
retrospective design; unrandomized, unblinded, and non-placebo controlled.  Selection bias 
in medication may have occurred as the choice of medication was based on physician 
preference. Also, small sample size resulted in inadequate power to evaluate the 
equivalence of the two medications.  
Momotani et al. evaluated the effect of maternal ingestion of PTU and methimazole on fetal 
thyroid status using cord sera at delivery (Momotani, 1997). The authors identified 249 
pregnant women with Graves’ disease who received either PTU or methimazole during 
their pregnancy. Of these 249 women, 77 (30.9%) had received at least four weeks of 
therapy, 34 (44.2%) with PTU and 43 (55.8%) with methimazole. Controls consisted of 32 
healthy women with no history of thyroid disease and who delivered at term.  
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Serum samples from mother and fetus were assayed for free FT4 and TSH. No statistical 
difference was observed in mean fetal free FT4 or fetal TSH between the PTU and 
methimazole treated groups. Low fetal free FT4 was seen in 6% of the PTU group and 7% of 
the methimazole group. High fetal TSH rates were 21% in the PTU group and 14% in the 
methimazole group. The relationship between maternal dose and fetal thyroid status was 
not significant; low doses of PTU were associated with high TSH in 21% of infants and low 
doses of methimazole were associated with high TSH in 14% of infants. The authors 
concluded that the two agents were similar regarding the effects on fetal thyroid status, and 
the selection of PTU over methimazole to treat hyperthyroidism during pregnancy was not 
justified (Momotani, 1997). The trial appeared to be well designed and utilized a direct 
measure of fetal thyroid status at birth. Potential bias may have existed as medication 
selection was based solely on provider preference. The selection process was not explained 
regarding how pregnant women with Graves’ disease and those who served as controls 
were identified.  
Azizi et al. evaluated the methimazole’s effect on intellectual development of children 
whose mothers received methimazole during pregnancy but not during lactation (Azizi, 
2002). The authors identified 23 children, ages 3 to 11 years, of mothers who were treated 
with methimazole during pregnancy and 30 children, ages 3 to 11 years, of mothers who 
were not treated with methimazole during pregnancy. All mothers delivered at term and 
there were no congenital malformations in either group. Methimazole-exposed mothers 
received methimazole doses up to 20 mg per day. All neonates were euthyroid at the time of 
delivery.  
No difference between the methimazole-treated group and the control in serum T3, T4, or 
TSH concentrations was observed. Physical characteristics such as weight and height were 
similar in both groups. A psychologist blinded to methimazole exposure used the Wechsler 
Preschool and Primary Scale of Intelligence (WPPSI) to detect a difference in verbal and 
performance IQ between the two groups.  No difference in verbal or performance IQ 
between the two groups of children was shown. Total IQ for the methimazole-treated group 
was 11711; IQ for the control group was 11314. The authors concluded that no detrimental 
effects on the physical or intellectual development occurred in those children exposed to 
methimazole during pregnancy (Azizi, 2002). The main strength of this study was the single 
blinded psychologist evaluation of child intellect using the WPPSI exam. Unfortunately, the 
WPPSI is an intelligence test designed for children ages 2 years 6 months to 7 years 3 
months and the study population included children 3-11 years of age. Other limitations to 
this study were a small sample size and low exposure dose of methimazole. 
3. Conclusion 
The selection of PTU over methimazole as the drug of choice to treat Graves’ disease during 
pregnancy should not be based on misleading statements in the literature that PTU has less 
placental transfer than methimazole, that PTU leads to less fetal hypothyroidism, or that 
exposure to methimazole during pregnancy leads to a decreased intellectual function in 
children. The United States Food and Drug Administration classifies both PTU and 
methimazole as a Category D because of the potential for fetal hypothyroidism, rather than 
potential teratogenicity. The ACOG recommends that either PTU or methimazole may be 
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used to treat pregnant women with hyperthyroidism. However, the Endocrine Society 
recommends PTU as a first line drug, especially during the first trimester (Abalovich, 2007).  
Clinical data shows that PTU and methimazole are equally efficacious in pregnant women 
with hyperthyroidism (Wing, 1994; Momotani, 1997). However, the possible association 
between methimazole and fetal anomalies such as aplasia cutis, esophageal atresia, and 
choanal atresia may present methimazole a less desirable first line treatment option than 
PTU. Although a causal relationship between methimazole and these fetal anomalies has not 
been established in clinical trials, the possibility of a relationship still exists. Therefore, in the 
absence of a compelling indication for the use of methimazole, PTU should still be 
considered as the first line agent in the treatment of Graves’ disease during pregnancy. 
However, methimazole should be considered a viable second choice if the patient is 
intolerant to PTU, has an allergic reaction to PTU, or fails to become euthyroid on PTU. 
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